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A Ab bs st tr ra ac ct t
Stalling of RNA polymerase II near the promoter has recently been found to be much more
common than previously thought. Genome-wide surveys of the phenomenon suggest that it is
likely to be a rate-limiting control on gene activation that poises developmental and
stimulus-responsive genes for prompt expression when inducing signals are received.
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The recruitment of RNA polymerase II (Pol II) to the
promoter has been generally believed to be the rate-limiting
step in gene activation [1]. However, a series of discoveries
made since the mid-1980s, combined with recent genome-
wide studies, suggest that many developmental and induci-
ble Drosophila and mammalian genes, prior to their expres-
sion, contain Pol II bound predominantly in their promoter
proximal regions in a ‘stalled’ state [1-8]. Activation of the
stalled polymerase is thought to be responsible for the
expression of these genes [1].
Distinct sets of accessory factors are associated with Pol II
stalling and its escape from stalling, acting either by direct
interaction with Pol II, or by manipulating the chromatin
environment - for example, by affecting histone modifica-
tions by histone methyltransferases (HMTs) or histone
acetyltransferases (HATs) [1]. Proteins associated with Pol II
stalling include the DRB sensitivity-inducing factor (DSIF)
and the negative elongation factor (NELF) [9,10], whereas
proteins such as the positive transcription-elongation factor-b
(P-TEFb) complex, and the general transcription factors
TFIIS and TFIIF contribute to escape from stalling [11,12].
These latter proteins enable Pol II to begin transcription
elongation on induction by heat shock, for example. Thus, all
the factors mentioned above may serve as a stalling
checkpoint to poise genes for prompt expression.
Although initial studies revealed that Pol II stalling is
present on several genes, it has recently been found that Pol
II stalling is more common than previously thought [13-16].
Technologies such as ChIP-chip (chromatin immunoprecipi-
tation in combination with genomic DNA microarrays) allow
transcriptional regulation to be examined genome wide
[17,18]. Through the ENCODE (Encyclopedia of DNA
Elements) project [19], in which 1% of the human genome
has been extensively analyzed, and through genomic studies
in  Drosophila, human embryonic stem cells (hESCs) and
other human cell lines, Pol II stalling is now seen as a
genome-wide phenomenon. Moreover, it is enriched at
highly regulated genes that are essential for responses to
stimuli and for embryonic development [13,14]. In addition,
stalled Pol II signals are associated with active histone
modification marks, including trimethylation of lysine 4 on
histone H3 (H3K4me3) and acetylation of H3 lysine 9 and 14
(H3K9ac and H3K14ac) [16]. Thus, Pol II promoter-
proximal stalling could help to provide an active chromatin
environment and prepare developmental and stimulus-
responsive genes for timely expression [1,20]. However, for a
gene to proceed to transcriptional elongation, additional
histone modifications are necessary [16]. In this article, we
review the mechanisms of Pol II stalling, with a focus on recent
genomic and epigenomic findings, and discuss the biological
implications of the widespread stalling phenomenon.P Po ol l   I II I   s st ta al ll li in ng g   a an nd d   t tr ra an ns sc cr ri ip pt ti io on n   e el lo on ng ga at ti io on n
Pol II promoter-proximal stalling was first described in Droso-
phila heat-shock-inducible genes (for example, Hsp70) using
ultraviolet-crosslinking and chromatin immunoprecipitation
(UV ChIP), which captures the specific proteins and their
bound DNA in vivo [4]. Pol II was found to be recruited to
the promoter of the uninduced Hsp70  gene, where it
initiates RNA synthesis but stalls after synthesis of 20-50
nucleotides of RNA [1,21]. Heat-shock stimulation enabled
Pol II to escape from the Hsp70 promoter-proximal region
and transcribe the full-length RNA. Thus, the regulation of
Pol II stalling rather than of transcription initiation is rate-
limiting for expression of this gene. After this initial
discovery, Pol II stalling was observed in more than a dozen
Drosophila and viral (HIV) genes, as well as in mammalian
genes (Myc, Junb, and Fos), in studies using UV ChIP and
nuclear run-on methods [1-8].
Pol II stalling was found to result from repression of transcript
elongation by at least two protein complexes: DSIF and NELF
[9,10]. ChIP assays showed that both DSIF and NELF are co-
localized with the stalled polymerase in the promoter-proximal
regions of uninduced Drosophila heat-shock genes [9,10]. The
mechanisms by which DSIF and NELF regulate Pol II stalling
are still under investigation. As NELF has been found to bind to
RNA, it is possible that NELF exerts its repressive function
through interaction with the nascent RNA [22].
The negative effects of DSIF and NELF on transcriptional
elongation are relieved by the action of factors that include
the P-TEFb complex, TFIIF and TFIIS [11,12] (Figure 1). The
P-TEFb complex includes the cyclin-dependent kinase-9
(CDK9), and cyclin T. P-TEFb facilitates the release of Pol II
from stalling by phosphorylating DSIF, NELF and the
carboxy-terminal domain (CTD) of the largest Pol II subunit
(Rpb1) at its Ser2 residue [8,11]. In addition, TFIIS also
helps Pol II to escape from promoter-proximal regions to
carry out full-length gene transcription. Stalled polymerases
are prone to backtracking along the DNA template, such that
the 3’-OH of the nascent RNA becomes misaligned with the
Pol II active site. By associating with the stalled Pol II, TFIIS
enables transcription elongation to continue by stimulating
the intrinsic RNA cleavage activity of Pol II to generate a
new 3’-OH end that is aligned with the active site [12].
Moreover, TFIIF, eleven-nineteen lysine-rich in leukemia
(ELL), and elongin also help to overcome stalling and stimu-
late Pol II transcription [1]. It is thought that TFIIF functions
mainly during the promoter-escape stage, whereas ELL and
elongin exert their effects once the nascent RNA transcript is
eight to nine nucleotides long [1]. After Pol II escapes from
the promoter-proximal regions, NELF dissociates from the
elongation complex while DSIF, TFIIS and P-TEFb remain
associated and continue to stimulate full-length gene trans-
cription (Figure 1) [1,9,12]. Identification and characteri-
zation of additional elongation factors will certainly further
our current understanding of Pol II stalling and its escape.
G Ge en no om me e- -w wi id de e   P Po ol l   I II I   s st ta al ll li in ng g   p ph he en no om me en na a
Until very recently, Pol II stalling was only known at the
promoters of a limited number of genes. Large-scale trans-
criptional regulation studies have enabled Pol II locations to
be examined on a whole-genome scale. ChIP-chip experi-
ments in both human and Drosophila  using tiling oligo-
nucleotide microarrays have demonstrated that Pol II
stalling is a genome-wide phenomenon and more common
than previously thought [17,18]. Kim et al. [15] showed that,
in addition to genes, such as Fos, that were known to have
stalled Pol II, large numbers of promoters of human genes
are bound by the Pol II preinitiation complex (PIC),
although no expression was detected for these genes. These
authors used specific antibodies against the PIC components
of Pol II and the general transcription factor TFIID in ChIP-
chip assays to map global PIC-binding sites in human
primary fibroblast IMR90 cells. Promoter occupancy by the
PIC was correlated with the genome-wide expression profiles
of IMR90 cells. Kim et al. found that more than 600 genes
were bound by the PIC but were not expressed. Obviously,
regulatory mechanisms other than Pol II recruitment to the
promoters are necessary to express these transcripts.
More recently, Muse et al. [13] reported a genome-wide
search using ChIP-chip for Pol II promoter-proximal stalling
in Drosophila. Among the genes bound by Pol II, some carry
uniform Pol II binding throughout the gene, including the
coding region, whereas in others Pol II binding signals were
prominent in the promoter regions, and either absent or
present at a low level within the full-length genes, consistent
with the unique features of stalled Pol II. The genes with
stalled Pol II showed low or no expression, whereas the
uniformly bound genes showed a good correlation between
Pol II occupancy and expression level. Other evidence
supported the notion that the promoter-enriched binding
was indeed due to Pol II stalling. Permanganate footprinting
assays were carried out to test promoter melting by
monitoring the reactivity of thymine residues. The hyper-
reactivity of single-stranded thymine residues confirmed the
presence of the stalled polymerase in the transcription
bubble [23]. In addition, NELF occupancy was also detected
via ChIP at the genes with stalled Pol II. Depleting NELF by
RNA interference significantly decreased Pol II signals in the
promoter region only and not throughout the gene.
Interestingly, Gene Ontology analysis revealed that the genes
bound by stalled polymerase are enriched in developmental
and stimulus-responsive genes involved in cell differentiation,
cell-cell signaling and immune response pathways. Finally, it
was shown that the stalled Pol II could be rapidly released
upon gene induction, such as with UV irradiation [13].
Using similar methods, Zeitlinger et al. [14] reported a
comprehensive Pol II ChIP-chip study in Drosophila
embryos. This study took advantage of a mutant embryo that
consists of mesodermal precursor cells alone. Neuronal- and
ectodermal-specific genes are repressed in this mutant
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In these cases, there is a much higher Pol II signal associated
with the 5’ region of the gene than the 3’ region, and neuronal
and ectodermal developmental genes were over-represented
among the genes with stalled Pol II. On the other hand,
ubiquitously expressed genes, such as genes for ribosomal
components, exhibited uniform Pol II binding signal
throughout the entire gene and a high level of expression.
Zeitlinger et al. [14] also found genes that lacked Pol II binding
altogether. These genes were enriched in genes for adult
functions that do not need to be expressed in the embryo.
C Co on nn ne ec ct ti in ng g   c ch hr ro om ma at ti in n   s st tr ru uc ct tu ur re e   w wi it th h   P Po ol l   I II I   s st ta al ll li in ng g
In addition to polymerase binding, an ‘open’ chromatin
structure is essential for active transcription. Various cova-
lent histone modifications around the transcription start site
are thought to be important for nucleosome depletion and
chromatin decondensation, which enable Pol II to move
forward and transcribe a DNA template. The most common
chromatin modifications include histone acetylation by HAT
and methylation by HMT, which can alter the properties of
chromatin and affect nucleosome repositioning. Genome-wide
studies in Saccharomyces cerevisiae and Drosophila have
shown that trimethylation of H3K4, and acetylation of H3K9
and H3K14 are usually associated with active transcription
[1,16,24]. In humans, the correlation between Pol II
occupancy and histone marks is likely to be more complex.
As mentioned above, large numbers of human genes have
Pol II bound at their promoter-proximal regions [15,16,25].
In addition, Guenther et al. [16] found that most annotated
genes are associated with H3K4me3, H3K9ac and H3K14ac
modifications in the promoter regions, although more than
half of these genes are inactive. This is true not only in
hESCs but also in differentiated cells, including primary
hepatocytes and B cells [16]. Most genes that are bound by
Pol II initiate transcription, but only genes with histone H3
trimethylation of lysine 36 (H3K36me3) and dimethylation
of lysine 79 (H3K79me2) proceed to elongation and produce
a mature transcript (Figure 2). Furthermore, quantitative
reverse transcription-PCR (RT-PCR) showed that the genes
that lack these additional histone marks do bind Pol II but at
a level lower than the actively transcribed genes, and
produce mainly short 5’ transcripts of fewer than 70
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F Fi ig gu ur re e   1 1
RNA polymerase II promoter-proximal stalling and subsequent escape to transcriptional elongation. At many genes, RNA polymerase II (Pol II) stalls after
the initiation of transcription, producing a short transcript typically less than 50 nucleotides long (left). Escape from stalling (right) is induced by
developmental or environmental signals. In the stalled complex, only Ser5 of the carboxy-terminal domain (CTD) of Pol II is phosphorylated [9]. The
P-TEFb complex (composed of CDK9 and cyclin T) facilitates release of Pol II from stalling by phosphorylating DSIF, NELF and the carboxy-terminal
domain of Pol II at Ser2 residues [8,11]. See text for details of other proteins shown in the diagram.
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5’nucleotides [16,18]. This observation is consistent with the
findings of Barski and colleagues on genome-wide DNA
methylation [25]. In addition, studies in the ENCODE
Project [18] and by Weber et al. [26] revealed that H3K4me2
and H3K4me3 are enriched at unmethylated CpG island
promoters, regardless of gene-expression status, suggesting
that these histone marks may protect DNA from methylation
and irreversible transcriptional silencing [18,26]. It is
presently unclear whether chromatin modifications are the
result of transcriptional events, or facilitate them, or both.
For example, H3 trimethylation of lysine 36 by the enzyme
Set2 associated with the elongating transcription complex
might alter chromatin structure and thereby facilitate
subsequent rounds of transcription [1,27].
P Po ol l   I II I   s st ta al ll li in ng g   a an nd d   n ne ew w   t tr ra an ns sc cr ri ip pt ti io on n
Recent studies of the transcriptome using microarrays or
sequencing have disclosed large amounts of transcriptional
activity throughout the human genome, with many of the
transcripts being present as polyA+ RNA [18,28-30]. The
biological role of this ‘unannotated’ transcription, much of
which is not expected to encode proteins, remains elusive. In
particular, it was reported that short transcribed sequences
of less than 200 nucleotides are clustered at the 5’ and 3’
ends of genes, producing the so-called promoter-associated
sRNAs (PASRs) and termini-associated sRNAs (TASRs) [31].
Intriguingly, the approximate lengths of one major class of
PASRs are 26, 38 and 50 nucleotides, which is consistent
with the lengths of the short transcripts reported to be
produced as a result of Pol II stalling. However, there are
usually multiple PASRs in the promoter region, not
necessarily starting from the same site. Whether these
represent multiple transcriptional start sites and the
relationship between these PASRs and Pol II stalling are not
yet clear. Finally, Pol II binding signals are also observed at
the 3’ ends of transcripts. It is possible that Pol II also pauses
upon termination of transcription (Z Lian, A Karpikov, J
Lian, MC Mahajan, S Hartman, M Gerstein, MS and SM
Weissman, unpublished data). Further study is necessary to
reveal the role of Pol II stalling in global transcription. The
emerging technology of massively parallel sequencing will
facilitate this effort [32-34].
T Th he e   i im mp pl li ic ca at ti io on n   o of f   g ge en no om me e- -w wi id de e   P Po ol l   I II I   s st ta al ll li in ng g   a an nd d
f fu ut tu ur re e   p pr ro os sp pe ec ct ts s
What is the broad implication of Pol II stalling beyond the
heat-shock response [4]? The genomic studies discussed in
this review suggest that Pol II stalling is much more
widespread than previously thought, and could serve as a
rate-limiting step in transcriptional regulation to prepare
organisms to respond to dynamic environmental and
developmental changes. The prompt generation of gene
products is crucial for the development and survival of the
organism. Zeitlinger et al. [14] found that genes with stalled
Pol II were highly enriched among developmental genes that
are destined to be transcribed very soon - within 12 hours.
Furthermore, Pol II promoter-proximal stalling could help
to establish an active chromatin structure and allow prompt
regulation of gene expression upon environmental stimuli
and developmental signals. However, it is not clear how
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F Fi ig gu ur re e   2 2
Histone-modification patterns associated with Pol II stalling and escape. Histone modifications typical of ( (a a) ) genes with stalled Pol II and ( (b b) )   after Pol II
escape to transcription elongation. Stalled Pol II signals are associated with active histone-modification marks, including histone H3 trimethylation on
lysine 4 (H3K4me3) and acetylation of lysine 9 and 14 (H3K9ac, H3K14ac) [16]. For transcript elongation to proceed, not only the histone modification
marks mentioned above are necessary; additional histone modifications, including H3 trimethylation on K36 (H3K36me3) and dimethylation on K79
(H3K79me2) are also needed [16]. The colored bars indicate the location of the histone modifications on the transcripts.
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genes and whether the deposition of the histone marks
depends on Pol II occupancy. Only about 70% of the genes
marked by H3K4me3 or H3K9ac and K14ac are associated
with Pol II promoter-proximal binding [16]. How Pol II
stalling is regulated also remains to be investigated. As noted
above, data from Hsp70 indicate that stalling is likely to be
mediated through a repressive mechanism. One possible
developmental regulator of Pol II stalling may be the protein
Snail, which represses mesodermal gene expression in
Drosophila embryos [14,35].
Further research is needed to identify additional factors that
play important roles in Pol II stalling and the escape from
stalling to transcriptional elongation. For example, the loss
of key factors such as NELF and DSIF does not completely
eliminate Pol II stalling. Also, there are indications from co-
immunoprecipitation assays that additional elongation
activators interact with the P-TEFb kinase, but the evidence
is not conclusive [11]. Lastly, the issue of how stimuli and
developmental signals trigger the elongation machinery to
release the stalled Pol II will be of prime interest for future
investigations.
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